Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Formulary management
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,114,833

« Back to Dashboard

Which drugs does patent 8,114,833 protect, and when does it expire?

Patent 8,114,833 protects SAXENDA and VICTOZA and is included in two NDAs. There has been one Paragraph IV challenge on Victoza.

This patent has eighteen patent family members in ten countries.

Summary for Patent: 8,114,833

Title:Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Abstract: The present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Inventor(s): Pedersen; Tina Bjeldskov (Smorum, DK), Bonde; Claude (Lyngby, DK), Engelund; Dorthe Kot (Holte, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/435,977
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk Inc
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes8,114,833► SubscribeY
Novo Nordisk Inc
liraglutide recombinant
SOLUTION;SUBCUTANEOUS022341-001Jan 25, 2010RXYesYes8,114,833► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,114,833

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2003 01719Nov 20, 2003

International Patent Family for Patent: 8,114,833

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2004290862► Subscribe
BrazilPI0416743► Subscribe
Canada2545034► Subscribe
China102784386► Subscribe
China104826116► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.